Tegaserod is a 5-HT4 agonist manufactured by Novartis and sold under the names Zelnorm and Zelmac for the management of irritable bowel syndrome and constipation.

[2] The drug functions as a motility stimulant, achieving its desired therapeutic effects through activation of the 5-HT4 receptors of the enteric nervous system in the gastrointestinal tract.

[4] On 30 March 2007, the United States Food and Drug Administration requested that Novartis withdraw tegaserod from shelves.

[5] The FDA alleged a relationship between prescriptions of the drug and increased risks of heart attack or stroke.

[7] In a large cohort study based on a US health insurance database, no increase in the risk of cardiovascular events were found under tegaserod treatment.